361 PROSTATE SAFETY AND EFFECTIVENESS OF TESTOSTERONE REPLACEMENT THERAPY IN MALE HYPOGONADISM: FINAL RESULTS FROM THE LARGEST INTERNATIONAL TRIAL INVOLVING 1493 PATIENTS

2011 ◽  
Vol 10 (2) ◽  
pp. 130
Author(s):  
M. Zitzmann ◽  
J. Hanisch ◽  
A. Mattern ◽  
M. Maggi
Keyword(s):  
Replacement Therapy ◽  
Testosterone Replacement ◽  
Testosterone Replacement Therapy ◽  
Male Hypogonadism ◽  
International Trial

scholarly journals A Case of Male Osteoporosis: A 37-Year-Old Man with Multiple Vertebral Compression Fractures

2017 ◽  
Vol 2017 ◽  
pp. 1-7
Author(s):  
Suhaib Radi ◽  
Andrew C. Karaplis
Keyword(s):  
Bone Mass ◽  
Replacement Therapy ◽  
Fragility Fractures ◽  
Testosterone Replacement ◽  
Vertebral Compression Fractures ◽  
Testosterone Replacement Therapy ◽  
Male Hypogonadism ◽  
Mineral Density ◽  
Compression Fractures

While the contributing role of testosterone to bone health is rather modest compared to other factors such as estradiol levels, male hypogonadism is associated with low bone mass and fragility fractures. Along with stimulating physical puberty by achieving virilization and a normal muscle mass and improving psychosocial wellbeing, the goals of testosterone replacement therapy in male hypogonadism also include attainment of age-specific bone mineral density. We report on a 37-year-old man who presented with multiple vertebral compression fractures several years following termination of testosterone replacement therapy for presumed constitutional delay in growth and puberty. Here, we discuss the management of congenital hypogonadotropic hypogonadism with hyposmia (Kallmann syndrome), with which the patient was ultimately diagnosed, the role of androgens in the acquisition of bone mass during puberty and its maintenance thereafter, and outline specific management strategies for patients with hypogonadism and high risk for fragility fractures.

scholarly journals Testosterone replacement therapy in men who conceived with intracytoplasmic sperm injection: nationwide register study

2020 ◽  
Vol 182 (4) ◽  
pp. 423-428 ◽  
Author(s):  
Angel Elenkov ◽  
Yahia Al-Jebari ◽  
Yvonne Lundberg Giwercman ◽  
Aleksander Giwercman
Keyword(s):  
Replacement Therapy ◽  
Intracytoplasmic Sperm Injection ◽  
Testosterone Replacement ◽  
Fertility Treatment ◽  
Testosterone Replacement Therapy ◽  
Male Hypogonadism ◽  
Testosterone Deficiency ◽  
Cox Regression Analysis ◽  
Infertile Men ◽  
Co Morbidity

Objectives Male hypogonadism is associated with higher risk of co-morbidity and premature mortality. It is, therefore, of utmost importance to identify young men who are at the highest risk of testosterone deficiency and who may benefit from preventive measures. In this context, infertile men constitute a high-risk group. The extent of testosterone replacement therapy (TRT) among infertile men, defined as men who have to undergo assisted reproduction for fatherhood, is currently unknown. Therefore, we evaluated the pattern of prescription of TRT in the years following child conception among men who have fathered children with the help of intracytoplasmic sperm injection (ICSI) or in vitro fertilization (IVF). Design By sourcing data from national population registries, hazard ratio (HR) for subsequent TRT was assessed for IVF and ICSI-treated men and compared to those who conceived spontaneously with age Cox regression analysis adjusted for age, educational level and previous intake of medicines for metabolic diseases. Results ICSI and IVF fathers had increased incidence of newly prescribed TRT compared to fathers conceiving spontaneously (ICSI: HR = 3.81, 95% CI = 3.09–4.69, P < 0.001; IVF: HR = 1.54, 95% CI = 1.15–2.05, P = 0.003). After adjustment for prescription of medication for one or more components of the MetS prior to TRT, the risk estimates attenuated but remained robust both for ICSI-treated (HR = 3.17 (95% CI: 2.56–3.9) and IVF-treated men (HR = 1.06 (95% CI: 1.05–1.07). Conclusion Men who have to utilise powerful techniques, such as ICSI for fathering children, may be at risk for testosterone deficiency. Routine endocrine evaluation of men seeking fertility treatment is hence warranted.

Society for Endocrinology guidelines for testosterone replacement therapy in male hypogonadism

2021 ◽  
Author(s):  
Channa Jayasena ◽  
Richard A. Anderson ◽  
Sofia Llahana ◽  
Julian Barth ◽  
Finlay MacKenzie ◽  
...  
Keyword(s):  
Replacement Therapy ◽  
Testosterone Replacement ◽  
Testosterone Replacement Therapy ◽  
Male Hypogonadism
Sign in / Sign up

Export Citation Format

Share Document